Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
As more people seek natural or non-drug ways to maintain their health, products containing probiotics have flooded the marketplace. While safe and tolerable, this study discovered that the probiotic S. boulardii does not appear to have any significant beneficial effects for patients with Crohn's disease who are already in remission.
In this randomized, double-blind, placebo-controlled trial, the probiotic yeast S. boulardii was tested as a preventive therapy in patients with moderately severe Crohn's disease who were currently in remission following steroid or salicylate therapies. At the end of the one-year follow-up period, 50 percent of patients had relapsed - 47.5 percent in the S. boulardii group and, similarly, 53.2 percent in the placebo group. Further, the time-to-relapse was not statistically different between patients treated with S. boulardii or placebo.
While this probiotic showed no positive effects for Crohn's disease patients, further studies are needed to determine the potential therapeutic efficacy of probiotics in other forms of IBD, such as ulcerative colitis, and pouchitis.
Probiotics are living microscopic organisms, or microorganisms, that scientific research has shown to benefit an individual's health. S. boulardii, a probiotic made from a strain of yeast and sold in local drug stores or supermarkets in the form of capsules, has been demonstrated to be effective in the treatment of traveler's diarrhea, diarrhea occurring in subjects infected with the human immunodeficiency virus and the prevention of diarrhea associated with antibiotics.
Clinical Gastroenterology and Hepatology Volume 11, Issue 8 , Pages 982-987, August 2013 doi:10.1016/j.cgh.2013.02.021
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Crohn's / IBD category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
American Gastroenterological Association. "Relapse in Crohn's disease patients not prevented by probiotics." Medical News Today. MediLexicon, Intl., 16 Aug. 2013. Web.
11 Dec. 2013. <http://www.medicalnewstoday.com/releases/264839>
American Gastroenterological Association. (2013, August 16). "Relapse in Crohn's disease patients not prevented by probiotics." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/264839.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.